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Abstract
Endometriosis is a disorder that affects 5% of the normal population but is present in up to 40% of
women with pelvic pain and/or infertility. Recent evidence suggests that the endometrium of
women with endometriosis exhibits progesterone insensitivity. One endometrial protein that
fluctuates in response to progesterone is the estrogen receptor-alpha (ER alpha), being down-
regulated at the time of peak progesterone secretion during the window of implantation. Here we
demonstrate that the biomarker of uterine receptivity, beta 3 integrin subunit, is reduced or absent
in some women with endometriosis and that such defects are accompanied by inappropriate over-
expression of ER alpha during the mid-secretory phase. Using a well-differentiated endometrial cell
line we showed that the beta 3 integrin protein is negatively regulated by estrogen and positively
regulated by epidermal growth factor (EGF). By competing against estrogen with various selective
estrogen receptor modulators (SERMs) and estrogen receptor agonists and antagonists, inhibition
of expression of the beta 3 integrin by estrogen can be mitigated. In conclusion, we hypothesize
that certain types of uterine receptivity defects may be caused by the loss of appropriate ER alpha
down-regulation in the mid-secretory phase, leading to defects in uterine receptivity. Such changes
might be effectively treated by timely administration of the appropriate anti-estrogens to artificially
block ER alpha and restore normal patterns of gene expression. Such treatments will require
further clinical studies.
Introduction
Uterine receptivity is regulated by the cyclic secretion of
ovarian steroids as a consequence of follicular develop-
ment and subsequent ovulation. As first described in the
uterus by its ability to bind estrogen [1], the classic estro-
gen receptor (ER-alpha), increases in response to estrogen
during the proliferative phase, and is diminished in
response to progesterone during the secretory phase [2].
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Progesterone receptors (PR) undergo similar changes; we
and others previously reported that expression of both ER-
alpha and PR are down-regulated at the time of implanta-
tion, particularly in the epithelial compartment [3-5].
While progesterone is an effective anti-estrogen, its role is
to reduce ER-alpha concentration rather than to act as a
competetive inhibitor of E2 binding, thereby rendering
the endometrium resistant to estrogen during the window
of implantation. This phenomenon has now been
observed in several mammalian species [6-8].
While steroid hormones were classically described as
stimulating gene expression, we now recognize from
genomic studies that steroid hormones can also inhibit
specific genes [9,10]. In endometrium, the decline in ER-
alpha may be a critical event, releasing an inhibitory influ-
ence on specific genes and providing a signal for endome-
trial receptivity to commence. The highly specialized and
specific mid-secretory repertoire of endometrial gene
expression coincides with a reduction in the expression of
ER-alpha [10]. Based on such studies, we now suggest that
the combination of progesterone action and coincident
estrogen withdrawal is required to stimulate key implan-
tation-specific events in the mid-secretory phase of the
menstrual cycle.
Early implantation is a complex process involving syn-
chronous and complementary events on both maternal
and embryonic surfaces. It is now well-established that
many proteins are expressed specifically at the time when
embryos implant [11,12]. The timing of implantation has
now been firmly established, occurring around 7 to 10
days after ovulation, corresponding to days 21 to 24 of an
idealized 28 day menstrual cycle [13]. Integrins are one of
many endometrial proteins that turn on or off around this
time in a woman's cycle [14,15], and the study of their
patterns of expression has yielded substantial information
about the factors that regulate endometrial receptivity in
the human [16,17]. One of these integrins is the alpha v/
beta 3 integrin that is expressed on the luminal and glan-
dular epithelium of the endometrium. Its appearance at
the time of implantation and its aberrant expression in a
variety of settings including luteal phase defect, endome-
triosis, polycystic ovarian syndrome (PCOS) and tubal
disease suggests a critical role for this protein [18-21]. We
recently demonstrated that the reduction in endometrial
beta 3 integrin expression in PCOS was associated with
elevated expression of ER-alpha and an over-expression of
steroid receptor coactivators [20]. In the present report we
examine the basis for this effect of estrogen on this partic-
ular marker of uterine receptivity and study women with
endometriosis as another group who appear to inappro-
priately express high levels of ER-alpha during the win-
dow of implantation.
Materials and methods
Patient samples
For these studies we used endometrial samples obtained
from 38 volunteers who had normal menstrual cycles and
proven fertility at various times in the menstrual cycle
(proliferative, n = 7; early secretory = 22; mid-secretory, n
= 13; late secretory = 6). Some of these samples were
obtained in women undergoing bilateral tubal ligation,
each found to be free of endometriosis at laparoscopy.
The 13 mid-secretory samples were obtained in fertile
controls that were recruited and paid for their participa-
tion. In addition, 19 mid-secretory endometrial biopsies
were obtained from women with infertility that subse-
quently had endometriosis documented by laparoscopy.
Each of these endometrial samples were selected because
they lacked epithelial expression of the alpha v/beta 3
integrin, despite having normal, "in phase" histologic
changes consistent with day 21 to 24 of the menstrual
cycle, according to the dating criteria of Noyes et al [22].
All mid-secretory samples were obtained and timed to the
urinary LH surge (Ovuiquick, Quidel, San Diego, CA). All
samples were formalin-fixed and paraffin embedded. His-
tologic stage (endometrial dating) was assigned by two of
the investigators (RAL and BAL). Samples were eliminated
from further consideration if there was evidence of histo-
logic delay that exceeded 3 days compared to the expected
endometrial dating based on urinary LH testing. The
acquisition and use of human tissue for this study was
approved by the Institutional Review Board at the Univer-
sity of North Carolina at Chapel Hill and Greenville Hos-
pital System, Greenville, SC.
Immunohistochemistry
Immunostaining for ER-alpha was performed on 5-to 6-µ
sections of formalin fixed, paraffin-embedded endome-
trial biopsies using the Vectastain Elite ABC kits (Vector
Laboratories, Inc.,Burlingame, CA). Diaminobenzidine
(Sigma, St. Louis, MO) was used as the chromagen. Tissue
sections were deparaffinized in xylene and hydrated in a
series of graded ethanols. Following a rinse in PBS, pH
7.4, endogenous peroxidase activity was quenched upon
incubation for 30 min with 0.3% H2O2 in absolute etha-
nol, followed by a 10-min rehydration in PBS. Tissue sec-
tions were heated in a microwave for 12 min in antigen
retrieval solution (10 mm citrate buffer) before incuba-
tion with primary antibody. After initial incubation with
blocking serum for 30 min at room temperature (4% nor-
mal goat serum), sections were incubated with mouse
monoclonal antibodies against human ER-alpha (Novo-
castra, New Castle upon Tyne, UK) overnight at 4 C. Neg-
ative controls were analyzed on adjacent sections
incubated without primary antibody. Each primary anti-
body was serially diluted to achieve maximum sensitivity
and specificity. A PBS rinse was followed by treatment of
secondary antibody consisting of biotinylated goat anti-Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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mouse antibody for 30 min. After this incubation, sec-
tions were washed and incubated with avidin:biotinylated
horseradish peroxidase macromolecular complex for 60
min. Visualization of peroxidase was carried out by add-
ing diaminobenzidine and incubated for 10 min to com-
plete the reaction. As a final step, sections were
counterstained with hematoxylin, dehydrated in a graded
series of ethanols, cleared with xylene, and a coverslip
placed over Permount for evaluation by light microscopy.
The resulting staining was evaluated using a Nikon micro-
scope (Tokyo, Japan), by a single observer (B.A.L.) with-
out knowledge of the specimen's identity. Assessment of
staining intensity and distribution was made using the
semi-quantitative histologic score (HSCORE) system in
the glandular and luminal epithelium and in the stromal
compartment. HSCORE was calculated using the follow-
ing equation: HSCORE: ∑ Pi (i + 1), where i represents the
intensity of staining ranging from 1, 2, or 3, (representing
weak, moderate or strong, respectively) and Pi represent-
ing the percentage of stained endometrial stromal and
epithelial cells for each intensity, varying from 0–100%.
Cell Culture and Western Blot Analysis
Ishikawa cells, the well differentiated endometrial carci-
noma cell line, were obtained from Dr. M. Nishida
(Kasumigaura National Hospital, Tsuchiura-shi, Ibaraki-
ken, Japan) and maintained in MEM (Life Technologies,
INC., Grand Island, NY) containing 5% charcoal stripped
fetal bovine serum (FBS), 1% pencillin-streptomycin (Life
Technologies, INC., Grand Island, NY) and 2 mM L-
glutamine (Life Technologies, INC., Grand Island, NY) at
37°C in the presence of 5% CO2. The culture medium
was changed every 2–3 days. This cell line contains a func-
tional estrogen receptor and as evident by estrogen-
induced alkaline phosphatase enzyme activity bioassay,
has been successfully used as a measure of estrogenic
activity in these cells [23,24]. Cells were treated in phenol
red-free DMEM/F12 media with 0.5% heat-inactivated
charcoal-stripped FBS, 1% pencillin-streptomycin and 2
mM L-glutamine. Cells plated onto 100 mm dishes were
exposed to medium alone (control) or medium contain-
ing 17β-estradiol (E2; 10-8 mol/L; Sigma) and/or epider-
mal growth factor (EGF; 10 ng/ml) individually or in
combination with the estrogen antagonist, ICI 182780
(10-6 mol/L; Zeneca Pharmaceuticals, Wilmington, DE) or
C225 antibody (30 nM/ml; monoclonal antibody that
neutralizes the EGF receptor, provided by Imclone, Inc.
(New York, NY). In other experiments cells were treated
with and with E2 (10-8 mol/L; Sigma), estriol (E3; 10-8
mol/L; Sigma) or equimolar concentrations (10-8M) of
selective estrogen receptor modulators (SERMs: Clomi-
phene Citrate, Tamoxifen, Raloxifene) The time of expo-
sure in each experiment was 72 h.
For immunoblotting of Ishikawa cell extracts, cells treated
as described above were harvested individually and cell
pellets obtained from the respective treatments were
resuspended in RIPA extraction buffer (10 mM Tris-HCl
[pH 8.0], 10 mM EDTA [pH 8.0], 150 mM NaCl, 1% NP-
40, and 0.5% SDS) containing protease-inhibitor cocktail
(Boehringer Mannheim, Indianapolis, IN). After centrifu-
gation at 10 000 × g for 10 min, protein concentrations
were determined using the Bio-Rad protein assay kit (Bio-
Rad Laboratories, Hercules, CA). Total proteins (100 µg
from each treatment) were denatured in Laemmli buffer,
electrophoresed on 10% SDS-containing polyacrylamide
gel and transferred to nitrocellulose membrane. Blots
were blocked for 1 h in TBST (20 mM Tris [pH 7.5], 137
mM NaCl, and 0.4% Tween-20) containing 10% nonfat
dry milk. Blots were washed twice for 5 min each time in
TBST, then incubated overnight with a 1:1000 dilution of
monoclonal antibody against alpha v/beta 3 integrin
(SSA6; a generous gift from James Hoxie, University of
Pennsylvania, Philadelphia, PA) while rocking at 4°C.
The blots were then washed twice for 30 min each time
with TBST, followed by incubation for 1 h at room tem-
perature with peroxidase-conjugated anti-mouse IgG sec-
ondary antibody while rocking. After washing twice for 30
min each time with TBST, the immunoreactive protein
complexes were detected by enhanced chemilumines-
cence (Amersham Pharmacia Biotech Inc., Piscataway,
NJ). The results depicted are representative of 2 independ-
ent experiments.
Statistical Analysis
Comparisons between treatment groups were analyzed
using ANOVA with Scheffe's correction for multiple com-
parisons using 95% confidence interval (p < 0.05). Analy-
sis was performed on a Dell PC with GraphPad Prism 4
software.
Results
The pattern of expression for ER-alpha changed through-
out the menstrual cycle, as judged by immunohistochem-
istry. As shown in Figures 1A–C and 2A–C, the temporal
and spatial pattern of ER-alpha was dynamic, with
increased expression in glandular, luminal, and stromal
compartments in the proliferative and early secretory
phases, and a subsequent decline in the mid to late-secre-
tory phases. Based on HSCORE determinations, the
expression of ER-alpha in all three cell types was signifi-
cantly lower in the secretory than the proliferative phase.
Luminal epithelium exhibited reduced ER-alpha immu-
nostaining relative to glandular epithelium. Stromal cells
also were devoid of ER-alpha immunostaining during the
time of maximal uterine receptivity in normal fertile sam-
ples. Later in the secretory phase, ER-alpha immunostain-
ing returned to the stromal compartment but little if anyReproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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immunostaining was observed in the epithelium in nor-
mal fertile controls.
Women with endometriosis who exhibited an aberrant
lack of the alpha v/beta 3 integrin, as a group exhibited a
significantly higher level of ER-alpha expression in epithe-
lial cells compared to normal fertile controls. Examples of
this are shown in Figure 1D and 1E. A comparison of ER-
alpha staining intensity and distribution (HSCORE) is
also shown in Figure 2D comparing glandular and lumi-
nal ER-alpha distribution only. Note the higher levels of
ER-alpha immunostaining in both cell types in women
with endometriosis and suspected defects in uterine
receptivity compared to normal women during the mid-
secretory phase.
To understand the mechanism of the action of estrogen
on beta 3 integrin expression, we used the hormone
responsive, well-differentiated, Ishikawa cell line. These
cells mimic the pattern of gene expression for endometrial
epithelium and provide a model to study factors that reg-
ulate specific genes in human endometrium [23,25-29].
As shown in Figure 3, using western blotting analysis, we
show that estrogen strongly inhibits the expression of the
beta 3 integrin subunit in Ishikawa cells, while EGF signif-
icantly increases its expression. Blockade of the EGF recep-
tor with a neutralizing antibody (C225) mitigates this
effect by EGF. Likewise, E2 counteracts the stimulatory
effect of EGF on beta 3 expression. The absolute estrogen
antagonist, (ICI 182780) released the inhibitor effect of
estradiol on beta 3 integrin expression, as well. This exper-
iment suggests that the beta 3 gene product is regulated in
endometrial epithelium by dual mechanisms that
includes both stimulatory and inhibitory components
and that estrogen inhibition appears to be dominant over
EGF stimulation.
If inhibitory factors block the expression of beta 3
integrin, we next asked how different estrogens or anti-
estrogens might compare as potential treatments for loss
of the beta 3 integrin. To examine the effect of various
selective estrogen receptor modulators to reverse this
inhibitor effect of estrogen, we pretreated Ishikawa cells
with estradiol and then added equimolar quantities of
either the weak estrogen (estriol; E3), the SERMs clomi-
phene citrate, tamoxifen, raloxifene and the anti-esrogen
ICI 182780. As noted in Figure 4, tamoxifen and clomi-
phene citrate did little to restore normal beta 3 integrin
expression. ICI 182780 was the most potent anti-estrogen
in terms of reversing inhibition of beta 3 protein. Surpris-
ingly, raloxifene was a fairly potent anti-estrogen in the
endometrial cells, as it induced reasonable inhibition of
the negative effect of estradiol on beta 3 integrin expres-
sion in Ishikawa cells.
Discussion
Estrogen action has traditionally been considered
mitogenic and stimulatory in most target cells. During the
proliferative phase, estrogen stimulates a large number of
genes including c-fos and c-jun, cell cycle proteins and the
estrogen receptor itself [30,31]. Exposed to unopposed
estrogen, the endometrium undergoes hypertrophy and
hyperplasia and eventually risks becoming neoplastic in
the absence of cyclic progesterone exposure. As shown in
the present study, estrogen appears to inhibit expression
of specific proteins, a role we would argue is confined to
select genes that are expressed during the window of
implantation. While estrogen is a major hormone in the
proliferative phase, it was previously argued that estrogen
is unnecessary for the normal development of the secre-
tory phase endometrium [32]. In our view, the disappear-
ance of ER-alpha at the time of implantation as seen in
most mammalian species, argues that continued ER-alpha
expression may be detrimental to the development of
uterine receptivity, or at least a sign of other dysfunction
in the endometrial cycle.
Based on expected steroid receptor changes, the loss of ER
during the mid-secretory phase provides a time in the
cycle when mitoses cease and implantation occurs. In this
study we documented, again, this decline in ER-alpha that
has previously been described [3,4]. Such changes in ster-
oid receptors may account for the four stages of the
endometrial cycle as defined by recent DNA microarray
studies [10]. In the first, estrogen works alone to stimulate
ER-alpha and PR isoforms and to increase expression of a
host of genes necessary for cell division and tissue growth.
With ovulation, in the early secretory phase, progesterone
acts to halt cell division and to induce secretory changes.
In the third (mid-secretory) phase, ER-alpha largely disap-
pears, providing for the first time, the opportunity for pro-
gesterone to act alone, specifically targeting the stroma
[3]. The stroma contributes paracrine activity in response
to progesterone, stimulating epithelial gene expression
indirectly [16]. During the late luteal phase, ER-alpha
appears to return to the stromal compartment, reflecting
the time of sloughing and regeneration that will soon fol-
low if pregnancy does not occur.
The elevation in ER-alpha that we describe in this study,
corresponds to the lack of beta 3 integrin in selected
patients with endometriosis. We described similar find-
ings in women with polycystic ovarian syndrome (PCOS).
This is another condition associated with infertility and
pregnancy wastage. While ER-alpha is elevated in PCOS
and beta 3 levels are low, the pathophysiology may be
quite different between the two diagnoses. In the former,
chronic estrogen may alter the complement of steroid
receptor coactivators that are present; in endometriosis,
elevations in aromatase have been described, possiblyReproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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Immunohistochemistry of ER-alpha in normal cycling women from the proliferative with inset showing luminal epithelium (A),  early secretory (B) and mid-secretory (C) endometrium Figure 1
Immunohistochemistry of ER-alpha in normal cycling women from the proliferative with inset showing luminal epithelium (A), 
early secretory (B) and mid-secretory (C) endometrium. Other samples from the mid-secretory endometrium from women 
with endometriosis shows increased and inappropriate expression of the ER-alpha protein in glandular and stromal compart-
ments (D and E) compared to normal mid-secretory endometrium (C). Bar = 50 µm.Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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Box and whisker plots are shown depicting the semi-quantitative immunohistochemical staining (HSCORE ± SD) for ER-alpha  in normal women throughout the menstrual cycle in proliferative, early, mid and late secretory glandular (A) and luminal (B)  epithelium and in stroma (C) Figure 2
Box and whisker plots are shown depicting the semi-quantitative immunohistochemical staining (HSCORE ± SD) for ER-alpha 
in normal women throughout the menstrual cycle in proliferative, early, mid and late secretory glandular (A) and luminal (B) 
epithelium and in stroma (C). In a separate analysis, glandular and luminal ER-alpha HSCOREs were compared between normal 
fertile mid-secretory endometrium and similar samples in women with endometriosis and suspected defects in uterine recep-
tivity (D). Significance was based on ANOVA with Bonferroni correction; * = p < 0.01, ** = p < 0.001. Abbreviations in the fig-
ure: Prolif = proliferative phase, ES = early secretory, MS = mid-secretory, LS = last secretory, gl = glandular epithelium, St = 
stroma, LU = luminal epithelium, Osis = endometrium from women with endometriosis. Note that the horizontal bars in the 
box and whisker plots designate the 10th, 25th, 50th, 75th, and 90th percentile distribution of the data and standard error bars 
are not shown in this figure.Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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raising the local production of estrogen. Alternatively,
faulty progesterone receptors have been reported in this
disorder. In this study, we document that ER-alpha is
increased in women with suspected defects in uterine
receptivity lacking the EGF stimulated and estrogen inhib-
ited gene, beta 3.
We suspect that there will be many genes other than beta
3 integrin subunit that are regulated in concert during
implantation in response to EGF and the loss of ER-alpha.
There are likely to be many other endometrial genes that
are inhibited by E2 and, like the beta 3 integrin protein,
are only expressed when ER-alpha is down-regulated
around the mid-secretory phase. Conversely, any failure
to down-regulate ER alpha in infertile women may predis-
pose to altered gene expression, including failure to
express essential proteins associated with uterine receptiv-
ity [19]. Such defects have been described in the
endometrium of women with endometriosis [33,34],
luteal phase defect (LPD), and polycystic ovarian syn-
drom (PCOS) [19,20,35], each of which is associated with
either infertility or pregnancy loss.
What might account for the aberrant down-regulation of
ER-alpha by the time of implantation in all of these differ-
ent disorders? In LPD, the timing of ER-alpha down-regu-
lation is delayed, perhaps due to inadequate progesterone
levels in the serum [36]. For endometriosis patients, it is
Western blot for beta 3 integrin expression in Ishikawa cells treated with no treatment (con), or three days of estradiol (E2;  10-8M), estradiol plus the 10-6 M pure antagonist ICI 182,780 (E2 + ICI), epidermal growth factor (EGF; 10 ng/ml), EGF plus the  EGF receptor antagonist antibody C225 (EGF + C225), EGF + ICI, EGF + E2 + ICI and ICI alone Figure 3
Western blot for beta 3 integrin expression in Ishikawa cells treated with no treatment (con), or three days of 
estradiol (E2; 10-8M), estradiol plus the 10-6 M pure antagonist ICI 182,780 (E2 + ICI), epidermal growth factor (EGF; 10 ng/ml), 
EGF plus the EGF receptor antagonist antibody C225 (EGF + C225), EGF + ICI, EGF + E2 + ICI and ICI alone.Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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clear that the endometrium of women with endometriosis
is different from normal endometrium [33,34,37]. An
important difference between eutopic endometrium from
women with and without endometriosis is also inappro-
priate expression of aromatase [38,39]. If aromatase
increases local estrogen production within the
endometrium, this might alter the balance between estro-
gen and progesterone and could therefore account for the
elevation in ER-alpha observed in this study. Alterna-
tively, increased IL-6 has been demonstrated in the
endometrium of women with endometriosis. IL-6 was
recently shown in breast cancer cells to activate ER and
this could lead to increased ERα expression [40,41].
Whether this effect is mediated through modulation of
aromatase is not clear. In endometriosis patients, defects
in the progesterone receptor have been postulated [37].
Western blot showing the effect of estrogen and anti-estrogens on the inhibition of the beta 3 integrin subunit in Ishikawa cells Figure 4
Western blot showing the effect of estrogen and anti-estrogens on the inhibition of the beta 3 integrin subunit 
in Ishikawa cells. In control cells, the beta 3 integrin was expressed while 10 -8 M estradiol reduced that expression signifi-
cantly. E3 (estriol) was less potent than estradiol (E2) at inhibiting beta 3. Of the SERMS, in cells treated with E2 plus equimolar 
concentrations of other anti-estrogens and SERMs, a differential competitive antagonism occurred with the most potent antag-
onism by ICI 182,780. Raloxifene had an anti-estrogen effect on this well-differentiated endometrial cell line as well. Con = 
Control; E2 = estradiol; E3 + estriol; ICI = ICI 182,780, C = clomiphene citrate; T = tamoxifen; R = raloxifene.Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S9
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Loss of progesterone activity may result in the persistence
of ER-alpha, since down-regulation of ER is one of the pri-
mary actions of progesterone. Finally, in PCOS, we sus-
pect that elevated ER-alpha levels are also associated with
a decrease in uterine receptivity. In this case, however, the
failure to down-regulate ER-alpha may be due to a hyper-
sensitivity to estrogen, as evidenced by the over-expres-
sion of steroid receptor coactivators and ER-alpha itself
[20].
Thus, uterine receptivity defects may represent a common
pathway for many women with infertility. The presence of
ER-alpha in mid-luteal endometrium may be the best
biomarker of a dysfunctional endometrium. Treatment of
such defects might be designed to block the estrogen
receptor or to correct the underlying cause of its over-
expression. In women with elevated ER-alpha during the
window of implantation, short-term treatment with anti-
estrogens may prove useful. If Raloxifene were used, for
example, its anti-estrogenic blockage of ER-alpha activity
may result in a normalization of biomarkers of uterine
receptivity. To our knowledge, no one has suggested such
a novel use of anti-estrogens, to stimulate uterine receptiv-
ity. Alternatives to anti-estrogens might also include the
use of stronger progestins or the use of aromatase inhibi-
tors. Only appropriately designed clinical trials will we be
able to address these possibilities. Given the large number
of women that might be affected, (e.g. PCOS, endometri-
osis or LPD) the potential benefits are substantial. A sim-
ple and direct treatment to restore normal uterine
receptivity in the cycle of conception would truly be an
enormous advance in our approach to women with
implantation failure.
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